Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to take their knowledge of oncology market dynamics to the next level and wisely build investment portfolios comprised of company stocks that fight Bladder Cancer.
The Global Bladder Cancer Market was valued at USD 4.2 billion in 2023 and is projected to reach USD 6.1 billion by 2032 representing a compound annual growth rate (CAGR) of approximately 4.1%.
The increased incidence of bladder cancer diagnosis around the world is spurring the growth of the bladder cancer therapeutics market. According to the International Agency for Research on Cancer (IARC), 59% of bladder cancer cases are observed in the developed countries, with Belgium reporting the highest number of bladder cancer cases. Asia-Pacific is the fastest growing regional market across China, India, and Southeast Asia countries.
Major treatment types include Chemotherapy, Immunotherapy, Radiation, Surgery and Targeted Therapy. Cystoscopy tests maintained a prominent market share due to their primary function for direct visualization and biopsy collection.
For additional information on Bladder Cancer, please review the video by Medical Centric.